Nkarta Therapeutics

In August 2019, Nkarta announced a crossover Series B round financing of $114 million. Nkarta is developing genetically modified natural killer cells (NK) cell therapies for cancer.The Company’s lead program is an NKG2D CAR for the treatment of hematological malignancies and solid tumors.